Should I buy Acadia Pharmaceuticals (ACAD) stock or is it too late?

Acadia Pharmaceuticals · Health Care · price $30

See the full Acadia Pharmaceuticals (ACAD) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 58% of its targets hit on this sector (74 calls tested). It aims for $49 (+65 %), call made on August 18, 2026, maturing on August 18, 2027 (10 d ago).

The 1 reliable analyst $49+65 %

The 12 other firms $36+21 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $49 median. “The 12 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Acadia Pharmaceuticals

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Needham	56 %	+30.0 %	16	$41 +38%
UBS	67 %	+16.3 %	6	$49 +65%
Citigroup	57 %	+11.8 %	7	$40 +35%
RBC Capital	50 %	+7.6 %	18	$37 +24%
Cantor Fitzgerald	42 %	+5.5 %	24	$28 -6%
HC Wainwright & Co.	47 %	+3.0 %	19	$37 +24%
JP Morgan	20 %	-6.0 %	10	$34 +14%
JMP Securities	27 %	-12.2 %	15	$38 +28%

In short — Should you invest in Acadia Pharmaceuticals? Is it too late, still worth it? Analysts are fairly positive (77% buy, median target $36, i.e. +21%), and the most reliable on ACAD targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

77% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $36, i.e. +21% from the current price ($30).
The most reliable firm on ACAD, B of A Securities (100% hit rate, 3 scored calls), targets $30 (call made on June 30, 2026, maturing on June 30, 2027) (+1%) in its most recent call, and $29 (call made on March 25, 2026, maturing on March 25, 2027) (-2%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 3 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on ACAD

Median target $36 (+21%) · 13 ratings · Buy consensus

Strong Buy00%

Buy1077%

Hold323%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Acadia Pharmaceuticals now?

We won't decide for you. The facts: 77% of analysts rate it a buy, median target $36 (+21%), and B of A Securities (most reliable on ACAD, 100%) targets $30. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Acadia Pharmaceuticals?

Not according to analysts: the median target ($36) is still +21% above the current price ($30) (most reliable on ACAD: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Acadia Pharmaceuticals still worth investing in?

It depends on the gap between the price ($30) and its estimated value: analysts target $36 on median (+21%), with 77% buys (most reliable on ACAD: B of A Securities, 100%). Cross-check with their real reliability on ACAD and the cautions above. Information, not advice.

What's the main risk in buying ACAD?

The consensus is not unanimous: of 13 ratings, 3 are neutral.

→ Go deeper: the full Acadia Pharmaceuticals profile (consensus, analyst reliability, price target, performance).